x

Search for a clinical trial

* (*) mandatory field

PAC203: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients with Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Previously Treated with Ruxolitinib - GB

  • Type of clinical trial : Drug clinical trial
  • Recruiting project : -
  • Status : Ongoing trial
  • Funding body(ies) :
  • Geographic coverage : Global
  • Sponsor : Cti biopharma inc.
  • Website
    • Phase : II
  • Principal investigator of clinical trial

  • INFORMATION NOT PROVIDED
  • Institution: Information not provided - US
  • ADDRESS: NOT PROVIDED - US
  • UNITED STATES
  • More information
  • Phone  : -
  • Fax  : -
Last update: November 2020

Additional information

The documents contained in this web site are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.